Home > Boards > US Listed > Biotechs > Global Blood Therapeutics (GBT)

5 Best Mid-Cap Biotech Acquisition Targets

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Timetravelerdos Member Profile
 
Followed By 61
Posts 9,344
Boards Moderated 0
Alias Born 01/10/14
160x600 placeholder
GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease Program PR Newswire (US) - 12/2/2021 8:00:00 AM
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program GlobeNewswire Inc. - 12/2/2021 8:00:00 AM
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/24/2021 8:00:00 AM
GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire Inc. - 11/12/2021 8:00:00 AM
GBT Announces New Employment Inducement Grants GlobeNewswire Inc. - 11/8/2021 8:00:00 AM
Merck & Co, Moderna, BioNTech among premarket losers' pack Seeking Alpha - 11/5/2021 8:58:25 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:49:13 PM
Global Blood Therapeutics EPS misses by $0.02, misses on revenue Seeking Alpha - 11/4/2021 4:27:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2021 4:11:46 PM
GBT Reports Third Quarter 2021 Financial Results GlobeNewswire Inc. - 11/4/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2021 9:06:59 AM
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire Inc. - 11/4/2021 9:05:00 AM
Global Blood Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:37 PM
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor) GlobeNewswire Inc. - 11/1/2021 8:00:00 AM
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4 GlobeNewswire Inc. - 10/28/2021 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/12/2021 12:48:01 PM
Investing in These 2 Stocks Could Double Your Money, Say Analysts TipRanks - 10/7/2021 10:11:20 PM
GBT Announces New Employment Inducement Grants GlobeNewswire Inc. - 10/7/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/5/2021 4:06:01 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/24/2021 7:01:23 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/24/2021 7:01:03 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/24/2021 7:01:02 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/24/2021 7:01:01 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 9/24/2021 7:00:51 PM
GBT Announces Participation at the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 8:00:00 AM
Timetravelerdos   Monday, 12/30/19 04:33:03 PM
Re: None
Post # of 37 
5 Best Mid-Cap Biotech Acquisition Targets

2019 Q4 has been a great quarter for biotech investors and more M&A deals are expected in 2020.

With the FDA approval of Oxbryta, GBT is the perfect acquisition candidate for treating sickle cell disease.

Global Blood Therapeutics (GBT) - $9B
With a market cap of $4.9B, Global Blood Therapeutics is engaged in the innovation and commercialization of drugs to serve the needs of sickle cell disease (NYSE:SCD). SCD is an inherited blood disorder caused by a genetic mutation in the beta-chain of hemoglobin, leading to the formation of abnormal hemoglobin known as sickle hemoglobin. GBT went up 60% over 3 weeks since the company confirmed FDA approval of Oxbryta (voxelotor), company's main drug to treat sickle cell disease in adults and children 12 years of age and older.

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

Following suit, the European Medicines Agency (NYSEMKT:EMA) has also included voxelotor in its Priority Medicines (PRIME) program, while the European Commission (NYSE:EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD. Based on GBT's EHA corporate update in June, Oxbryta is addressing the needs of over 100,000 SCD patients in U.S. and 60,000 patients in Europe. The annual cost of SCD care is $200,000 per patient. An approved drug means R&D risks are largely absent and GBT is attractive to large Biopharma companies which seek to expand their drug pipelines without development risks.

Additionally, GBT started HOPE-KIDS2 which is to confirm there is a decreased risk of stroke for children 2 to 15 years old with Oxbryta. GBT also announced a collaboration with Syros Pharmaceuticals (SYRS) to discover, develop and commercialize novel therapies for sickle cell disease and beta thalassemia. On Dec 18, GBT secured $150M non-dilutive term loan to enhance its cash position for further development and commercialization, which clears any near-term dilution risks and places company in a great spot to negotiate a good deal with potential acquirers.

https://seekingalpha.com/article/4314536-5-best-mid-cap-biotech-acquisition-targets

Statements made are only my opinion. Do your own DD in order to make your Investment decisions.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences